Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three Oxford-based COVID-19 projects are among the first to benefit from a share of £20 million in government investment.

A bird's eye view of Oxford © Greg Smolonski

The three projects include work on an effective vaccine, enabling pre-clinical and clinical vaccine trials, as well as supporting researchers to develop manufacturing processes to produce a vaccine at a million-dose scale. Another project will examine how existing treatments could be repurposed to treat coronavirus.

Business Secretary Alok Sharma said, 'Whether testing new drugs or examining how to repurpose existing ones, UK scientists and researchers have been working tirelessly on the development of treatments for coronavirus. The projects we are funding today will be vital in our work to support our valuable NHS and protect people’s lives.'

Health Secretary Matt Hancock said, 'In the midst of a global health emergency the UK is using all its extensive research expertise to quickly develop new vaccines to target this international threat. This investment will speed up globally-recognised vaccine development capabilities and help us find a new defence against this disease.'

The projects receiving funding are supporting and encouraging the UK’s world-class researchers and experts to speed up coronavirus research including developing new vaccines and treatments. Oxford's funded projects are:

  • Professor Sarah Gilbert, (Jenner Institute, Nuffield Department of Medicine), £2.2 million for vaccine development and trials
  • Professor Peter Horby, (Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine), £2.1 million for research into the effectiveness of current drugs on COVID-19
  • Dr Sandy Douglas, (Nuffield Department of Medicine), £0.4 million, research into vaccine manufacturing capabilities

Read the full story, including details of the funded projects, on the University of Oxford website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.